Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
AbbVie is conducting a Phase 3 study titled ‘A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis.’ The study aims to evaluate the safety and efficacy of upadacitinib compared to dupilumab in pediatric patients with moderate to severe atopic dermatitis, focusing on adverse events and changes in disease activity.
The interventions being tested are upadacitinib, an oral tablet or solution, and dupilumab, a subcutaneous injection. Upadacitinib is intended to provide systemic treatment for atopic dermatitis, while dupilumab is administered as per its label instructions.
The study design is interventional with a randomized, parallel assignment. It employs a single-blind approach where the outcomes assessor is blinded. The primary purpose is treatment-focused, aiming to determine the comparative effectiveness of the drugs.
The study began on August 19, 2024, with a primary completion date yet to be announced. The latest update was submitted on June 30, 2025. These dates are crucial for tracking the study’s progress and potential market entry.
This study could impact AbbVie’s stock performance positively if results favor upadacitinib, potentially increasing investor confidence. The competitive landscape includes other companies developing treatments for atopic dermatitis, which may influence market dynamics.
The study is ongoing, with further details available on the ClinicalTrials portal.